Featured Publications
Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case–control analysis
Lind M, Robertson A, Silva J, Warner F, Coppi A, Price N, Duckwall C, Sosensky P, Di Giuseppe E, Borg R, Fofana M, Ranzani O, Dean N, Andrews J, Croda J, Iwasaki A, Cummings D, Ko A, Hitchings M, Schulz W. Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case–control analysis. PLOS Medicine 2022, 19: e1004136. PMID: 36454733, PMCID: PMC9714718, DOI: 10.1371/journal.pmed.1004136.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionBooster vaccinationPrior infectionOmicron infectionPrimary vaccinationMRNA vaccinationOdds ratioAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionPrior SARS-CoV-2 infectionTest-negative case-control analysisYale New Haven Health SystemTest-negative case-control studyCOVID-19 mRNA vaccinationSyndrome coronavirus 2 infectionOmicron variant infectionPrior infection statusCoronavirus 2 infectionCase-control studyCase-control analysisOdds of infectionRisk of infectionRace/ethnicityBooster dosesDate of test
2022
Use of Whole-Genome Sequencing to Estimate the Contribution of Immune Evasion and Waning Immunity on Decreasing COVID-19 Vaccine Effectiveness
Lind M, Copin R, McCarthy S, Coppi A, Warner F, Ferguson D, Duckwall C, Borg R, Muenker M, Overton J, Hamon S, Zhou A, Cummings D, Ko A, Hamilton J, Schulz W, Hitchings M. Use of Whole-Genome Sequencing to Estimate the Contribution of Immune Evasion and Waning Immunity on Decreasing COVID-19 Vaccine Effectiveness. The Journal Of Infectious Diseases 2022, 227: 663-674. PMID: 36408616, DOI: 10.1093/infdis/jiac453.Peer-Reviewed Original ResearchMeSH KeywordsCase-Control StudiesCOVID-19COVID-19 VaccinesHepatitis DHumansImmune EvasionSARS-CoV-2Vaccine EfficacyConceptsVaccine effectivenessImmune evasionDelta infectionVE estimatesSecond doseTest-negative case-control studySevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Whole-genome sequencingCOVID-19 vaccine effectivenessRespiratory syndrome coronavirus 2Syndrome coronavirus 2Case-control studyCoronavirus 2Calendar periodDelta variantInfectionDoseEvasionDaysLow effectivenessImmunityVariantsMIF is a common genetic determinant of COVID-19 symptomatic infection and severity
Shin JJ, Fan W, Par-Young J, Piecychna M, Leng L, Israni-Winger K, Qing H, Gu J, Zhao H, Schulz WL, Unlu S, Kuster J, Young G, Liu J, Ko AI, Garcia A, Sauler M, Wisnewski AV, Young L, Orduña A, Wang A, Klementina O, Garcia AB, Hegyi P, Armstrong ME, Mitchell P, Ordiz DB, Garami A, Kang I, Bucala R. MIF is a common genetic determinant of COVID-19 symptomatic infection and severity. QJM 2022, 116: 205-212. PMID: 36222594, PMCID: PMC9620729, DOI: 10.1093/qjmed/hcac234.Peer-Reviewed Original ResearchConceptsMacrophage migration inhibitory factorLow-expression MIF alleleCOVID-19 infectionMIF allelesCATT7 alleleHealthy controlsCOVID-19Serum macrophage migration inhibitory factorSymptomatic SARS-CoV-2 infectionHigh-expression MIF allelesHigher serum MIF levelsRetrospective case-control studySARS-CoV-2 infectionFunctional polymorphismsAvailable clinical characteristicsMultinational retrospective studySerum MIF levelsUninfected healthy controlsSymptomatic COVID-19Tertiary medical centerHealthy control subjectsCase-control studyMigration inhibitory factorCoronavirus disease 2019Common functional polymorphismsChange in covid-19 risk over time following vaccination with CoronaVac: test negative case-control study
Hitchings MDT, Ranzani OT, Lind ML, Dorion M, D'Agostini TL, de Paula RC, de Paula OFP, de Moura Villela EF, Scaramuzzini Torres MS, de Oliveira SB, Schulz W, Almiron M, Said R, de Oliveira RD, Vieira da Silva P, de Araújo WN, Gorinchteyn JC, Dean NE, Andrews JR, Cummings DAT, Ko AI, Croda J. Change in covid-19 risk over time following vaccination with CoronaVac: test negative case-control study. The BMJ 2022, 377: e070102. PMID: 35697361, PMCID: PMC9189440, DOI: 10.1136/bmj-2022-070102.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBrazilCase-Control StudiesCOVID-19COVID-19 TestingCOVID-19 VaccinesHumansSARS-CoV-2VaccinationVaccinesConceptsSymptomatic COVID-19Negative case-control studyCase-control studyHospital admissionOdds ratioCOVID-19Series completionCovid-19 related hospital admissionReverse transcription polymerase chain reaction testingTranscription polymerase chain reaction testingSevere COVID-19 outcomesSARS-CoV-2 infectionPolymerase chain reaction testingInactivated whole virus vaccineDoses of CoronaVacAcute respiratory illnessTest-negative controlsWhole virus vaccineRelated hospital admissionsHealthcare worker statusConditional logistic regressionCOVID-19 outcomesCOVID-19 symptomsMunicipality of residenceSARS-CoV-2
2021
Effectiveness of ChAdOx1 vaccine in older adults during SARS-CoV-2 Gamma variant circulation in São Paulo
Hitchings MDT, Ranzani OT, Dorion M, D’Agostini T, de Paula RC, de Paula OFP, de Moura Villela EF, Torres MSS, de Oliveira SB, Schulz W, Almiron M, Said R, de Oliveira RD, Silva PV, de Araújo WN, Gorinchteyn JC, Andrews JR, Cummings DAT, Ko AI, Croda J. Effectiveness of ChAdOx1 vaccine in older adults during SARS-CoV-2 Gamma variant circulation in São Paulo. Nature Communications 2021, 12: 6220. PMID: 34711813, PMCID: PMC8553924, DOI: 10.1038/s41467-021-26459-6.Peer-Reviewed Original ResearchMeSH KeywordsAgedBrazilCase-Control StudiesCOVID-19COVID-19 VaccinesFemaleHumansMaleMiddle AgedSARS-CoV-2ConceptsSingle doseOxford-AstraZeneca COVID-19 vaccineTest-negative case-control studySevere COVID-19 outcomesCOVID-19COVID-19-related deathsTwo-dose scheduleTwo-dose regimenCase-control studyCOVID-19 outcomesInter-dose intervalCOVID-19 hospitalizationCOVID-19 vaccineSARS-CoV-2ChAdOx1 vaccinePrimary endpointSecondary endpointsFirst doseSecond doseHigh prevalenceElderly individualsElderly populationVariant prevalenceVaccine supplyHospitalizationEffectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study
Ranzani OT, Hitchings MDT, Dorion M, D'Agostini TL, de Paula RC, de Paula OFP, Villela EFM, Torres MSS, de Oliveira SB, Schulz W, Almiron M, Said R, de Oliveira RD, Vieira da Silva P, de Araújo WN, Gorinchteyn JC, Andrews JR, Cummings DAT, Ko AI, Croda J. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. The BMJ 2021, 374: n2015. PMID: 34417194, PMCID: PMC8377801, DOI: 10.1136/bmj.n2015.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBrazilCase-Control StudiesCOVID-19COVID-19 Nucleic Acid TestingCOVID-19 VaccinesFemaleHumansMaleSARS-CoV-2Treatment OutcomeConceptsSymptomatic COVID-19Negative case-control studyCase-control studyHospital admissionVaccine effectivenessSecond doseDose regimenElderly populationCOVID-19Reverse transcription polymerase chain reaction testingTranscription polymerase chain reaction testingPolymerase chain reaction testingGamma variantInactivated whole virus vaccineAdjusted vaccine effectivenessTest-negative controlsWhole virus vaccineCOVID-19 statusCOVID-19 symptomsYounger age groupsMunicipality of residenceSARS-CoV-2RT-PCR testSelf-reported raceCoronaVac vaccineDiverse functional autoantibodies in patients with COVID-19
Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, Liu F, Zhou T, Israelow B, Wong P, Coppi A, Lucas C, Silva J, Oh JE, Song E, Perotti ES, Zheng NS, Fischer S, Campbell M, Fournier JB, Wyllie AL, Vogels CBF, Ott IM, Kalinich CC, Petrone ME, Watkins AE, Dela Cruz C, Farhadian S, Schulz W, Ma S, Grubaugh N, Ko A, Iwasaki A, Ring A. Diverse functional autoantibodies in patients with COVID-19. Nature 2021, 595: 283-288. PMID: 34010947, DOI: 10.1038/s41586-021-03631-y.Peer-Reviewed Original ResearchConceptsPeripheral immune cell compositionSARS-CoV-2 infectionCOVID-19Effects of autoantibodiesTissue-associated antigensSpecific clinical characteristicsInnate immune activationImmune cell compositionCOVID-19 exhibitCOVID-19 manifestsAnalysis of autoantibodiesSARS-CoV-2Functional autoantibodiesMouse surrogateClinical characteristicsVirological controlClinical outcomesImmune activationMild diseaseAsymptomatic infectionAutoantibody reactivityDisease progressionHealthcare workersHigh prevalenceAutoantibodies